Format

Send to

Choose Destination
Hepat Mon. 2015 Nov 28;15(11):e32418. doi: 10.5812/hepatmon.32418. eCollection 2015 Nov.

Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran.

Author information

1
Internal Medicine Department, Bam University of Medical Sciences, Bam, IR Iran.
2
Department of Gastroenterology, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, IR Iran.
3
Pharmaceutics Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, IR Iran.
4
Physiology Research center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, IR Iran.
5
Gastroenterology and Hepatology Research Centre, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, IR Iran.
6
Department of Immunology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran.
7
Department of Immunology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, IR Iran; Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, IR Iran.

Abstract

BACKGROUND:

Non-alcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease. Several studies suggest that pentoxifylline (PTX) can improve the disease outcome.

OBJECTIVES:

We aimed to compare the effect of pentoxifylline with placebo on liver aminotransferases and cytokines, including interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), and interleukin 8 (IL-8) in patients with NASH.

PATIENTS AND METHODS:

Thirty patients with NASH were included in the study, based on ultrasonography and 1.5-fold mean change from baseline serum levels of liver aminotransferases. Patients with NASH were randomized to receive 1200 mg PTX (the intervention group) or placebo (the placebo group) for 6 months. The serum levels of liver aminotransferases and cytokines were compared between the intervention and placebo groups, at various time points.

RESULTS:

The serum levels of liver aminotransferases were significantly reduced at 3 months and at 6 months, compared with baseline, in both groups. The serum levels of IL-6 were significantly decreased, in both groups, only at 6 months, compared with baseline. Compared to the placebo group, the serum level of TNF-α was significantly decreased in the intervention group, at 6 months. The serum level of IL-8 was increased, in both groups, after 6 months, without reaching clinical significance. There was no significant difference in serum levels of liver aminotransferases and cytokines, between intervention and placebo groups.

CONCLUSIONS:

Decreases in the serum levels of liver aminotransferases and cytokines, in both groups, are related to low-calorie diets and exercise, rather than PTX.

KEYWORDS:

Clinical Trial; Cytokines; Non-Alcoholic Fatty Liver Disease; Pentoxifylline

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center